GYS1 / Glycogen [starch] synthase, muscle · IHC design guide

Design Immunohistochemistry for GYS1

Plan GYS1 paraffin IHC around the cytoplasmic staining reported in most tissues, with abundant staining in muscle cells (HPA tissue IHC). Use the catalog antibody’s 2–5 μg/ml IHC range as a starting point (datasheet A03512-3), and interpret staining with the HPA reliability assessment in mind (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for GYS1 (IHC for GYS1): expected localisation Cytoplasmic staining (HPA tissue IHC), antibody A03512-3, validated IHC image, and IHC protocol steps — Printable **GYS1** IHC protocol sheet — expected localisation Cytoplasmic staining (HPA tissue IHC), antibody A03512-3, controls and protocol steps. Open the full GYS1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

GYS1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining (HPA tissue IHC)
	Staining pattern	Cytoplasmic staining in most tissues; abundant in muscle cells (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet A03512-3)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Tissue staining has medium RNA consistency (HPA tissue IHC)
	Regulation	Expression in glycogen-bearing cell types (UniProt)
	Isoform / epitope	2 isoforms; epitope coverage is unspecified (UniProt)

Section 1

Recommended GYS1 IHC & IF Protocols

The catalog antibody protocol uses EDTA pH 8.0 heat retrieval (datasheet A03512-3). The published IHC protocols below cover breast tumors and synovial tissue (PMC10242793; PMC6072843).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A03512-3)
Fixation	Image fixative and duration unreported (datasheet A03512-3); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet A03512-3); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A03512-3)
Primary antibody	Rabbit anti-GYS1, 2-5 μg/ml (datasheet A03512-3)
Primary incubation	Overnight at 4 °C (datasheet A03512-3)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A03512-3)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	GYS1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues, highly abundant in muscle cells. No signal in the no-primary control.

💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A03512-3); the breast tumor paper reports heat retrieval without specifying its buffer (PMC10242793).

Section 2

What Is the Expected GYS1 Staining Pattern?

GYS1 should appear chiefly in the cytoplasm across many tissues and be especially abundant in muscle cells (HPA: tissue IHC profile). Cytosol and microtubules are approved locations in ICC-IF (HPA: subcellular). It has no transmembrane segment or signal peptide (UniProt P13807 topology and processing). HPA rates its tissue IHC reliability Enhanced, while describing only medium agreement with RNA data and pending external verification (HPA: tissue IHC reliability).

What am I looking at on my slide?
Cytoplasmic staining in muscle cells and other expected cells.	This fits the reported tissue pattern; muscle cells are especially abundant (HPA: tissue IHC profile). Judge intensity within each tissue: high staining is recorded in several glandular and neuronal cell populations, while some other populations are low (HPA: tissue IHC levels). A weak cell is therefore not automatically a failed stain.
Predominantly nuclear, cell-surface, or extracellular staining.	These patterns depart from the reported cytoplasmic tissue pattern (HPA: tissue IHC profile). An exclusively cell-surface pattern also lacks support from GYS1 topology and processing (UniProt P13807). Treat the discordance as a possible artefact and check controls; compartment alone cannot identify its cause (general IHC practice).
Strong staining in a cell population reported as low.	Strong staining in chondrocytes, bone-marrow hematopoietic cells, or lung type II alveolar cells merits scrutiny (HPA: low tissue IHC levels). These are low observations, not validated negative controls (HPA: tissue IHC levels). Cross-reactivity or endogenous chromogenic activity is possible; compare control slides before assigning a cause (general IHC practice).
Diffuse color across cells, stroma, and blank areas.	A broad deposit that ignores cell boundaries is difficult to reconcile with the reported cellular pattern (HPA: tissue IHC profile). In chromogenic IHC, incomplete blocking, endogenous detection activity, or excessive detection background can produce nonspecific color (general IHC practice). Assess the background with a matched negative detection control.
No discernible staining in a suitable positive tissue.	Absent cytoplasmic signal in muscle is discordant with its reported abundance (HPA: tissue IHC profile). Confirm that the specimen contains the expected cells, then review the antibody and detection controls (general IHC practice). The HPA tissue record does not establish a GYS1-specific fixation or antigen-retrieval failure mechanism.

💡Expected GYS1 appearanceCall a section positive when expected cells show predominantly cytoplasmic signal, especially conspicuous in muscle (HPA: tissue IHC profile); isolated nuclear or diffuse cell-free color is suspect (HPA: tissue IHC profile; general IHC practice).

How each factor affects the staining
Cellular location and topology	Cytoplasmic tissue staining is the reference pattern (HPA: tissue IHC profile). GYS1 lacks a transmembrane segment, signal peptide, and propeptide (UniProt P13807 topology and processing). These facts support checking unexpected surface or extracellular color, but do not prove that every such deposit is nonspecific.
Tissue and cell context	The profile spans most tissues and is especially abundant in muscle cells (HPA: tissue IHC profile). Listed low populations are useful comparators, but the supplied record lists no negative population (HPA: tissue IHC levels). Do not score every faint cell as negative or require uniform intensity across tissues.
Antibody validation	One listed antibody has Enhanced IHC validation and another has Supported IHC validation (HPA: CAB007793 and HPA041598 antibody records). The overall tissue profile still has medium staining-to-RNA consistency and awaits external verification (HPA: tissue IHC reliability). Interpret an unexpected pattern with controls and independent evidence.
Isoforms and epitope scope	Two isoforms are recorded (UniProt P13807 isoforms). The supplied evidence gives no antibody epitope or isoform coverage, so a staining difference cannot be assigned to an isoform from this record. Fifteen modified residues are recorded, including phosphoserines (UniProt P13807 modified residues); antibody sensitivity to them is unspecified.
IF/ICC Q&A: what location is reported?	Cytosol and microtubules are approved ICC-IF locations, with images listed for A-431, U-251MG, and U2OS (HPA: subcellular). That observation can inform interpretation of cellular localization; it does not supply an IF/ICC protocol or establish how a paraffin-section chromogenic pattern will resolve microtubules.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Muscle-containing section is blank.	The result conflicts with reported abundance in muscle cells (HPA: tissue IHC profile); the failure point is undetermined.	Confirm muscle is present, inspect a known-positive control, and review primary-antibody and chromogenic detection steps (general IHC practice). Do not attribute the blank section specifically to fixation or retrieval without evidence.
Signal appears only in nuclei or at cell surfaces.	The distribution conflicts with cytoplasmic tissue staining (HPA: tissue IHC profile) and, for surface-only signal, with the absence of a transmembrane segment (UniProt P13807 topology).	Compare with a negative detection control and the expected cytoplasmic cells; review staining specificity before scoring those compartments as GYS1 (general IHC practice).
Color is widespread in stroma or outside cells.	Noncellular deposit is inconsistent with the reported cellular profile (HPA: tissue IHC profile). Endogenous chromogenic activity or detection background can contribute (general IHC practice).	Examine a control lacking primary antibody, check endogenous-activity blocking appropriate to the detection system, and reassess wash and detection conditions (general IHC practice).
A reported low cell population stains strongly.	The result differs from a low HPA observation but does not by itself prove cross-reactivity (HPA: low tissue IHC levels).	Compare the same cell population with a negative detection control and a positive tissue control; seek independent confirmation if the strong pattern persists (general IHC practice).
A few cells stain weakly while nearby cells stain strongly.	Intensity need not be uniform: HPA reports high staining in some cell populations and low staining in others (HPA: tissue IHC levels).	Identify and score the relevant cell types separately; use the tissue's reported pattern as context before treating weak cells as a technical failure (HPA: tissue IHC profile; general IHC practice).
Two antibodies give different patterns.	The listed antibodies have different IHC validation statuses (HPA: antibody records), and the supplied evidence does not specify their epitope or isoform coverage.	Compare each result against the cytoplasmic tissue profile and controls, then report the disagreement rather than choosing a pattern by intensity alone (HPA: tissue IHC profile; general IHC practice).

Source: UniProt P13807 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing GYS1 staining

IHC analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in a paraffin-embedded section of human breast cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-Glycogen synthase 1/GYS1 Antibody (A03512-3) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

A03512-3 · IHCIHC analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in a

IF analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in an immunocytochemical section of A431 cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 5 μg/mL rabbit anti-Glycogen synthase 1/GYS1 Antibody (A03512-3) overnight at 4°C. DyLight®488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:100 dilution and incubated for 30 minutes at 37°C. The section was counterstained with DAPI. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

A03512-3 · IFIF analysis of Glycogen synthase 1/GYS1 using anti-Glycogen synthase 1/GYS1 antibody (A03512-3). Glycogen synthase 1/GYS1 was detected in an

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/cerebral+cortex#imid_2133408

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/colon#imid_2133334

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/liver#imid_2133335

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000104812-GYS1/tissue/kidney#imid_2133352

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA041598; green = GYS1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for GYS1 IHC & IF

🧪Run breast first: glandular cells should stain (HPA: High in breast glandular cells). HPA detects GYS1 in all 45 scored tissues, so there is no HPA negative tissue; use no-primary and isotype controls, and expect cells without specific staining on the positive slide to remain at background rather than assigning a cell type as GYS1-negative (HPA: no negative rows).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: None in HPA: GYS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show GYS1 in A-431, U-251MG, U2OS, with annotated localisation: Microtubules (approved), Cytosol (approved) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control, a host- and isotype-matched nonimmune rabbit IgG control, and GYS1-knockout material as a biological negative (selected-SKU caption: rabbit primary antibody). For the breast section, block endogenous peroxidase and assess endogenous biotin background when using the caption’s biotinylated secondary, SABC, and DAB detection (selected-SKU tissue-IHC caption).

⚠️Feasibility: Paraffin-section IHC is documented with heat retrieval in EDTA at pH 8.0, followed by 2 μg/ml primary antibody overnight at 4°C; the caption reports no fixative, and no target-specific fixation window or fixation effect is supplied (selected-SKU tissue-IHC caption). ICC-IF images support cytosolic and microtubule localisation, but the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC (HPA: approved cytosol and microtubules; selected-SKU tissue-IHC caption). In breast sections, check glandular-cell staining against background from the biotin-based detection system (HPA: High in breast glandular cells; selected-SKU tissue-IHC caption: SABC/DAB).

HPA tissue IHC evidence for GYS1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Cerebellum	Cells in molecular layer	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: GYS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced GYS1 IHC Tips

Troubleshoot GYS1 staining in paraffin sections by checking retrieval, cellular distribution and controls before comparing signal intensity (datasheet A03512-3; HPA tissue IHC).

What retrieval should I use when GYS1 staining is weak in paraffin sections?

Begin with heat-mediated antigen retrieval in EDTA buffer at pH 8.0 (datasheet A03512-3). The catalog antibody produced a tissue IHC image after this retrieval, followed by 2 μg/ml primary antibody overnight at 4°C (datasheet A03512-3). If signal is weak, first compare a fresh section with the same EDTA procedure and include a known positive area on the slide; changes in heating or tissue handling can alter staining (standard IHC practice; HPA: highly abundant in muscle cells). Only then test an alternative retrieval condition on matched sections, recording both signal and tissue preservation rather than assuming stronger color means better specificity (standard IHC practice).

Could fixation explain variable GYS1 staining between paraffin blocks?

Target-specific GYS1 sensitivity to fixation is unknown: the selected tissue IHC caption says the section was paraffin embedded but does not state its fixative (datasheet A03512-3). Record each block’s fixative and fixation duration, then compare sections with the same EDTA pH 8.0 retrieval and 2 μg/ml primary antibody conditions (datasheet A03512-3; standard IHC practice). Include similarly processed positive tissue and a no-primary control so loss of antigen signal can be distinguished from changes in background (standard IHC practice). Do not attribute differences specifically to GYS1 phosphorylation or topology without a controlled fixation comparison (UniProt P13807: phosphoprotein, no transmembrane segment; standard IHC practice).

Where should GYS1 staining appear, and how should unexpected nuclear color be handled?

Expect predominantly cytoplasmic tissue staining, with abundant signal reported in muscle cells (HPA tissue IHC). The independent subcellular profile assigns GYS1 to cytosol and microtubules, so a structured cytoplasmic pattern can be plausible, but that profile does not establish what DAB should resolve in a paraffin section (HPA subcellular; standard IHC practice). For isolated nuclear color, inspect the hematoxylin counterstain and compare a no-primary control before calling nuclei positive (standard IHC practice). Score cytoplasmic signal separately from nuclear or extracellular deposits, and review neighboring intact cells for a reproducible pattern (HPA tissue IHC; standard IHC practice).

Can this antibody distinguish GYS1 isoforms or phosphorylation states in IHC?

GYS1 has 2 listed isoforms and multiple modified residues, including phosphoserines at positions 8, 11, 412, 641 and 645 (UniProt P13807). The supplied tissue IHC caption gives staining conditions but no immunogen, epitope map or phospho-specific validation, so it cannot establish isoform or phosphorylation-state selectivity (datasheet A03512-3). Interpret DAB intensity as staining by this antibody under the tested conditions, rather than as a direct measure of GYS1 activity (datasheet A03512-3; UniProt P13807 function). If that distinction matters, compare an independently validated isoform- or modification-specific reagent on matched sections and document its own controls (standard IHC practice).

How should I adapt the GYS1 question to multiplex immunofluorescence?

For multiplex IF, pair GYS1 with a marker identifying the cell population being assessed; muscle cells are a useful expected population, while glandular cells also show high tissue IHC staining in several sampled organs (HPA tissue IHC). Choose a fluorophore channel after checking tissue autofluorescence in an unstained section, and include single-stain controls to assess spectral bleed-through (standard IF practice). Permeabilize for intracellular access because GYS1 has no transmembrane segment and its reported locations are cytosol and microtubules, although the catalog antibody’s epitope is unspecified (UniProt P13807 topology; HPA subcellular; datasheet A03512-3). Optimize IF fixation and permeabilization independently: the supplied catalog caption documents tissue IHC, not this antibody’s IF performance (datasheet A03512-3).

How can I reduce diffuse DAB background without losing GYS1 signal?

Start by retaining the documented 10% goat serum block, 2 μg/ml primary antibody overnight at 4°C, and EDTA pH 8.0 retrieval as a reference condition (datasheet A03512-3). Compare a no-primary section and a section omitting the biotinylated secondary to locate background arising in the detection sequence (standard IHC practice; datasheet A03512-3: biotinylated goat anti-rabbit secondary and SABC/DAB). Block endogenous peroxidase before DAB development and check for endogenous biotin when using an avidin–biotin method (standard IHC practice; datasheet A03512-3: SABC/DAB). If background persists, titrate the primary on matched sections while preserving cytoplasmic staining in a positive area (HPA tissue IHC; standard IHC practice).

How should I quantify heterogeneous GYS1 staining across tissue regions? ⚠ ANSWER MARKED FOR VERIFICATION

Define intact tissue regions before scoring, and exclude folds, edges and necrosis according to the same rule for every section (standard IHC practice). For cellular staining, report the percentage of cytoplasm-positive cells and an H-score from 0–300 based on staining intensity; keep cell types separate where their abundance differs (standard IHC practice; HPA tissue IHC: cytoplasmic expression). Normalize positive counts to the number of evaluable cells, or positive area to evaluable tissue area in mm², rather than to the whole image (standard IHC practice). Compare sections processed with matched retrieval, antibody concentration and DAB development, using a common reference section to monitor run variation (datasheet A03512-3; standard IHC practice).

What distinguishes credible GYS1 staining from tissue or detection artefact?

A credible result follows a reproducible cytoplasmic pattern in intact cells and agrees with the expected cellular distribution; muscle cells are reported as highly abundant, and several glandular cell populations stain strongly (HPA tissue IHC). Dominant nuclear or extracellular color warrants review because the reported locations are cytosol and microtubules (HPA subcellular). Examine section edges and necrotic regions for uneven deposits, and compare no-primary and peroxidase-block controls before attributing DAB color to GYS1 (standard IHC practice; datasheet A03512-3: DAB detection). Treat agreement with expression patterns as supporting evidence rather than proof of antibody specificity, since HPA reports medium consistency and pending external verification (HPA tissue IHC).

Boster reagents

Best GYS1 / Glycogen [starch] synthase, muscle IHC Antibodies

A03512-3 has human paraffin-section IHC images and IF data from A431 cells (catalog image captions); its listed reactivity covers human, mouse and rat (catalog reactivity).

Real IHC data

Anti-Glycogen synthase 1/GYS1 Antibody ®

Cat # A03512-3

View product →

A03512-3 has IHC images from human breast cancer, lymphoma, placenta and renal clear cell carcinoma sections, plus IF data from A431 cells (catalog image captions). M03512 and M03512-2 list IHC and IF applications with human, mouse and rat reactivity (catalog applications and reactivity); P03512-2 lists IHC and IF with human and mouse reactivity (catalog applications and reactivity).

Which to pick: For tissue IHC, pick A03512-3: its own captions document staining in human paraffin sections after EDTA retrieval at pH 8.0, using 2 μg/ml primary antibody (A03512-3 IHC image captions); the fixative is unreported (A03512-3 IHC image captions). For IF/ICC, A03512-3 has an IF image from A431 cells at 5 μg/ml (A03512-3 IF image caption); M03512-2 is a rabbit monoclonal option listed for IF and IHC (M03512-2 catalog description and applications). For cross-species planning, A03512-3 and M03512-2 list human, mouse and rat reactivity, while P03512-2 lists human and mouse reactivity (catalog reactivity).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P13807 (GYS1_HUMAN, Glycogen [starch] synthase, muscle).
Human Protein Atlas. GYS1 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. GYS1 subcellular location (ICC-IF): Localized to the cytosol and microtubules..
Human Protein Atlas. GYS1 antibody validation summary (2 antibodies).
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. Journal of experimental & clinical cancer research : CR 2023 — PMC10242793.
Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 — PMC10684475.
Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer. MedComm 2024 — PMC10901283.
Glycogen Metabolism and Rheumatoid Arthritis: The Role of Glycogen Synthase 1 in Regulation of Synovial Inflammation via Blocking AMP-Activated Protein Kinase Activation. Frontiers in immunology 2018 — PMC6072843.
PubMed PMID:2493642 — UniProt-cited evidence.
PubMed PMID:7657035 — UniProt-cited evidence.
PubMed PMID:9010351 — UniProt-cited evidence.